Acadia Healthcare Co., Inc.

How big is Acadia Healthcare Co., Inc.?

As of Jun 18, Acadia Healthcare Co., Inc. has a market capitalization of $1.92 billion, with net sales of $3.16 billion and a net profit of $194.78 million over the latest four quarters. The company reported shareholder's funds of $3.07 billion and total assets of $5.96 billion as of Dec 24.

Market Cap: As of Jun 18, Acadia Healthcare Co., Inc. has a market capitalization of 1,920.75 million, categorizing it as a Mid Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Acadia Healthcare reported net sales of 3,156.41 million and a net profit of 194.78 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 3,073.72 million and total assets of 5,956.91 million.

What does Acadia Healthcare Co., Inc. do?

Acadia Healthcare Co., Inc. is a mid-cap provider of behavioral healthcare services, with recent net sales of $771 million and a net profit of $9 million. Key financial metrics include a P/E ratio of 8.00 and a debt-to-equity ratio of 0.70.

Overview: <BR>Acadia Healthcare Co., Inc. is a provider of behavioral healthcare services operating in the Pharmaceuticals & Biotechnology industry, with a market cap in the mid-cap bracket.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 771 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 9 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 1,920.75 Million (Mid Cap)<BR><BR>Key Metrics: <BR>P/E: 8.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.70 <BR>Return on Equity: 8.85% <BR>Price to Book: 0.63 <BR><BR>Contact Details: <BR>Address: 6100 Tower Cir Ste 1000, FRANKLIN TN : 37067-1509 <BR>Tel: 1 615 8616000 <BR>Website: https://www.acadiahealthcare.com/

Who are in the management team of Acadia Healthcare Co., Inc.?

As of March 2022, Acadia Healthcare Co., Inc.'s management team includes Independent Chairman Mr. Reeve Waud, CEO Ms. Debra Osteen, and several Independent Directors: Mr. Jason Bernhard, Mr. E. Perot Bissell, Mr. Michael Fucci, Ms. Vicky Gregg, and Mr. William Grieco. They are responsible for the company's strategic direction and governance.

As of March 2022, the management team of Acadia Healthcare Co., Inc. includes the following key individuals:<BR><BR>- Mr. Reeve Waud, who serves as the Independent Chairman of the Board.<BR>- Ms. Debra Osteen, who is the Chief Executive Officer and a Director.<BR>- Mr. Jason Bernhard, who is an Independent Director.<BR>- Mr. E. Perot Bissell, who is also an Independent Director.<BR>- Mr. Michael Fucci, another Independent Director.<BR>- Ms. Vicky Gregg, who serves as an Independent Director.<BR>- Mr. William Grieco, who is an Independent Director.<BR><BR>This team plays a crucial role in guiding the company's strategic direction and governance.

Should I buy, sell or hold Acadia Healthcare Co., Inc.?

Is Acadia Healthcare Co., Inc. technically bullish or bearish?

As of October 3, 2025, Acadia Healthcare's trend is neutral with mixed signals; it has outperformed the S&P 500 recently but underperformed year-to-date, showing a mildly bullish weekly MACD and a bearish monthly MACD.

As of 3 October 2025, the technical trend for Acadia Healthcare Co., Inc. has changed from mildly bearish to sideways. The current stance is neutral, with mixed signals across different time frames. The weekly MACD is mildly bullish, while the monthly MACD is bearish. The RSI shows no signal on the weekly chart but is bullish on the monthly. Bollinger Bands indicate a mildly bullish trend weekly and mildly bearish monthly. Daily moving averages are mildly bearish. KST and OBV are both mildly bullish on the weekly but bearish on the monthly.<BR><BR>In terms of performance, Acadia has outperformed the S&P 500 over the past week and month, with returns of 7.82% and 11.55% respectively, but has significantly underperformed over the year-to-date and longer periods.

Is Acadia Healthcare Co., Inc. overvalued or undervalued?

As of November 21, 2025, Acadia Healthcare Co., Inc. is fairly valued with a P/E ratio of 8 and lower valuation ratios than peers, despite a significant year-to-date stock decline of -60.81% compared to the S&P 500's 12.26% gain.

As of 21 November 2025, Acadia Healthcare Co., Inc. has moved from expensive to fair in its valuation grade. The company appears to be fairly valued based on its P/E ratio of 8, a price to book value of 0.69, and an EV to EBITDA of 6.69. In comparison to peers, Acadia's P/E ratio is lower than Encompass Health Corp. at 20.94 and The Ensign Group, Inc. at 32.46, indicating that Acadia may be undervalued relative to these companies.<BR><BR>Despite the fair valuation, Acadia has experienced significant declines in stock performance, with a year-to-date return of -60.81%, compared to a positive return of 12.26% for the S&P 500. This stark contrast in performance reinforces the notion that Acadia may be undervalued, especially when considering its lower valuation ratios relative to its peers in the pharmaceuticals and biotechnology industry.